Shenzhen Zhongge Biotechnology Co. Ltd. has identified interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors and derived PROTAC compounds reported to be useful for the treatment of autoimmune disorders, inflammatory disorders, cancer, transplant rejection and more.